Baricitinib plus remdesivir reduces time to recovery in COVID-19 patients in NIAID-sponsored ACTT-2 trial

This article was originally published here

ACTT-2 included more than 1,000 patients and began on May 8 to assess the efficacy and safety of a 4-mg dose of baricitinib plus remdesivir versus remdesivir in

The post Baricitinib plus remdesivir reduces time to recovery in COVID-19 patients in NIAID-sponsored ACTT-2 trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply